Precursor B-cell Lymphoblastic Leukemia Lymphoma

• EMA withdrawal · 2022-07-05
  EMA Withdrawn: Imatinib Actavis (imatinib) — Actavis Group PTC ehf

  EMA withdrawn Imatinib Actavis (imatinib) from the market, with indications including chronic myeloid leukemia, precursor B-ALL/lymphoma, my…

• CLINICAL_TRIALS withdrawal · 2017-04-10
  Clinical Trial Update: A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

  A clinical trial evaluating JCAR015 in adults with B-cell acute lymphoblastic leukemia has been withdrawn.